Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

5Total

Phase 4(3)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03656120Phase 2Unknown

A Study of Thienorphine Hydrochloride Tablets in Relapse Prevention Treatment of Opioid Dependence

Role: lead

NCT01825928Not ApplicableCompleted

An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence

Role: lead

NCT01813643Phase 4Terminated

A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis

Role: lead

NCT01822730Phase 4Completed

A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis

Role: lead

NCT01813656Phase 4Terminated

An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

Role: lead

All 5 trials loaded